To clarify whether CYP2C19 is involved in the overall metabolism of clarithromycin (CAM) or not, in vitro studies using human liver microsomes and recombinant CYPs were performed by an approach based on the disappearance rate of parent compound from the incubation mixture. In addition, the results of disappearance rate were compared with those obtained from the formation rates of the major metabolites of CAM, 14-(R )-hydroxy-CAM and N-demethyl-CAM.
Introduction
Clarithromycin (CAM) is a 14-membered macrolide antibiotic with a broad antibacterial spectrum 1, 2) and widely used for the treatment of Helicobacter pylori infection such as a triple therapy with omeprazole and amoxicillin. 3) Previous studies have shown that CAM is oxidized to the two major metabolites, 14-(R )-hydroxy-CAM and N-demethyl-CAM via hydroxylation at the 14-position and N-demethylation, respectively. 4, 5) The enzyme responsible for the formation of the two metabolites has been identiˆed as CYP3A by the in vitro study using human liver microsomes. 6) However, Furuta et al. reported that there is a gene-dose eŠect of CYP2C19 defective alleles on the mean area under the plasma concentration-time curves (AUC) of CAM after the coadministration of CAM and omeprazole. 7) They found that AUC of CAM was the highest in the poor metabolizer group, the second-highest in heterozygous extensive metabolizers group and the lowest in homozygous extensive metabolizers group of CYP2C19. 7) They speculated that CYP2C19 is associated with the metabolism of CAM to a certain extent, otherwise omeprazole may interfere more strongly with the metabolism of CAM by CYP3A4 in the poor metabolizer group because of high concentration of omeprazole in plasma in this group. 7) Measuring the metabolite's formation rate with a speciˆc metabolic pathway has generally been utilized for the identiˆcation of a CYP isoform in studies on drug metabolism. However, the usefulness of this conventional approach is limited for assessing the CYP isoform(s) responsible for the overall metabolism of drugs, since it requires information on the importance of the particular metabolic pathway in the overall metabolic clearance. Such information is not usually available. In the case of CAM, contribution of the formation of 14-(R )-hydroxy-CAM and N-demethyl-CAM from CAM to the overall metabolic clearance of CAM has not been clariˆed, although they are the major metabolites of CAM found in the urine of humans. 4, 5) Therefore, it remains possible that CYP2C19 is involved in the overall metabolism of CAM via the other metabolic pathway than 14-(R )-hydroxylation and N-demethylation.
In order to clarify this possibility, we studied the CYP isoforms involved in the overall metabolism of CAM using human liver microsomes by the disappearance rate of parent compound from the incubation mixture, and compared the results with those obtained from the conventional approach based on the formation of 14-(R )-hydroxy-CAM and N-demethyl-CAM.
Materials and Methods
Chemicals and reagents: Clarithromycin (CAM), 14-(R )-hydroxy-CAM, N-demethyl-CAM, and Ndemethyl-6-O-methyl erythromycin B (internal standard for N-demethyl-CAM) were synthesized at Taisho Pharmaceutical Co. Ltd. (Saitama, Japan). Erythromycin B (internal standard for CAM) was obtained from Abbott Laboratories (North Chicago, IL, USA). A derivatization reagent, 4-‰uoro-7-nitrobenzofurazan (NBD-F), was purchased from Dojindo Laboratories (Kumamoto, Japan). Testosterone and troleandomycin (TAO) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). 6b-Hydroxytestosterone and ketoconazole were obtained from Sumika Chemical Analysis Service (Osaka, Japan) and BIOMOL Research Lab., Inc. (Plymouth Meeting, PA, USA), respectively. Acetonitrile, methanol and other reagents of analytical grade were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Microsomal preparations from eleven diŠerent recombinant human CYP isoforms (i.e., CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9-Arg, CYP2C19, CYP2D6-Val, CYP2E1, CYP3A4, and CYP4A11) expressed in the human B lymphoblastoid cell line (AHH-1) were purchased from Gentest Corp. (Woburn, MA, USA). Microsomes derived from baculovirus infected insect cells that contained overexpressed CYP2C19 (Supersomes, Gentest Corp.) were also used for further assessing the involvement of CYP2C19. Inhibitory antibody to human CYP3A4 W 5 was purchased from Amersham International (Tokyo, Japan). The antibody is a polyclonal antibody raised in rabbits against rat CYP3A1 with approximately 95z inhibition of the testosterone 6b-hydroxylation catalyzed by the rat and human CYP3A subfamily, but this antibody does not inhibit the activities of CYP1A2, CYP2A6, CYP2B6, CYP2C8 W 9, CYP2D6 and CYP2E1 (data provided by Amersham).
Incubation conditions with human liver microsomes and recombinant human CYP isoforms: The basic incubation medium contained 0.3 mg W mL human liver microsomes, 4 mM MgCl2, 0.5 mM NADP, 2 mM glucose-6-phosphate, 1 IU W mL glucose-6-phosphate dehydrogenase, 100 mM potassium phosphate buŠer (pH 7.4), 0.1 mM EDTA and CAM, in aˆnal volume of 250 mL. Human liver microsomes were purchased from Gentest Corp (pooled human liver microsomes, H161) or prepared by diŠerential centrifugation from 9 human livers obtained as an excess material during liver surgery (fromˆve male and four female patients aged 44¿67 years). Before the study, use of human liver samples for the study was approved by the institutional ethics committee W institutional review board of International Medical Center of Japan (Tokyo, Japan). The substrate concentrations were 100 mM for the formation of metabolites and 1 mM for the depression of CAM unless otherwise stated. Those concentrations were almost double or well below the reported Km values of around 50 mM for N-demethylation and 14-(R )-hydroxylation of CAM. 6) Although data are not shown, the disappearance rate at a substrate concentration of 1 mM was not diŠerent from that of 5 mM in a preliminary study; thus, the substrate concentration used for the determination of intrinsic clearance was conˆrmed to be within the linearity. The mixture was incubated at 379 C in a shaking water bath for 10 or 20 min after the 1 min of preincubation. The reaction was terminated by addition of 100 mL of ice cold acetonitrile for the determination of metabolites or 100 mL of internal standard (erythromycin B, 3.125 mg W mL in acetonitrile) for the determination of CAM depression. After termination of the incubation, the mixture was centrifuged at 10,000 rpm for 10 min, and the supernatant was analyzed by HPLC.
The incubation conditions used for the recombinant human CYP isoforms obtained from genetically engineered B lymphoblastoid cells were essentially the same as those used for human liver microsomes, except for incubation time (120 min) and the concentration of microsomes used (1 mg W mL). The microsomes prepared from human B lymphoblastoid cells with vectors or containing cDNA-expressed NADPH-cytochrome c reductase were used for control incubations. HPLC assay: The determination of CAM or its metabolites in the incubation mixture was performed by the HPLC method of Ohtake et al. with slight modiˆca-tion. 8) In brief, for the determination of CAM and 14-(R )-hydroxy-CAM, an aliquot of supernatant (50 mL) prepared from the incubation mixture was directly injected into the HPLC system. The HPLC system consisted of a model LC-6A pump (Shimadzu, Kyoto, Japan), model SIL-6B autosampler (Shimadzu), model CTO-6A column oven (Shimadzu), model C-R4A integrator (Shimadzu) and NUCLEOSIL 100-5C18 column (150×4.0 mm internal diameter, GL Sciences Inc., Tokyo, Japan). The mobile phase consisted of acetonitrile: methanol: 0.05M phosphate buŠer (pH 6.5) (40:15:45 by volume) delivered at 0.8 mL W min. Column temperature was maintained at 409 C. The eluate was monitored by electrochemical detection (Coulochem model 5100A, Enviromental Sciences Associates, Bedford, MA, USA) with the electric potentials of the guard cell and theˆrst and second electrodes set at 0.95 V, 0.65 V and 0.9 V, respectively.
For the determination of N-demethyl-CAM, 100 mL of internal standard (N-demethyl-6-O-methyl erythromycin B, 2.5 mg W mL in acetonitrile), 100 mL of NBD-F (2 mg W mL in methanol), and 100 mL of 0.05M borate buŠer (pH 8.5) were added to an aliquot of supernatant (50 mL) prepared from the incubation mixture and reacted for 10 min at 609 C. Then the reaction mixture was cooled on ice, mixed with 0.005M hydrochloric acid (100 mL), and an aliquot (50 mL) was injected into the HPLC system. The chromatography was conducted with a reversed-phase column, COSMOSIL 5C8 (150×4.0 mm in internal diameter, Nacalai Tesque Inc., Kyoto, Japan). The mobile phase consisted of acetonitrile: methanol: water: phosphoric acid (55:3:42:0.01 by v W v) delivered at 1.2 mL W min. Column temperature was maintained at 409 C. The eluate was monitored by ‰uorescence detection (model FP-920, Jasco, Tokyo, Japan) with excitation and emission wavelengths set at 470 and 530 nm, respectively.
The determination limit was 0.25 mM for CAM, 0.09 mM for 14-(R )-hydroxy-CAM and 0.14 mM for Ndemethyl-CAM. Intra-assay coe‹cients of variation were º5z for all analytes.
Intrinsic clearance of CAM: The intrinsic clearance (CLint) values of CAM in nine diŠerent human liver microsomes were estimated from the volume of medium (V) and the half-life of substrate disappearance (T1 W 2 ) using the equation: CLint＝V×0.693 W T1 W 2.
9) The halflife of CAM in the incubation medium was calculated by the regression analysis of semi-logarithmic plots.
Non-speciˆc binding of CAM to microsomal protein was negligible.
Correlation study: The rates of N-demethylation and 14-(R )-hydroxylation or CLint of CAM were correlated with the metabolic activities of substrates toward the respective CYP isoforms using nine diŠerent human liver microsomes.
Phenacetin O-deethylation (CYP1A2), 10) coumarin 7-hydroxylation (CYP2A6), 11) S-mephobarbital Ndemethylation (CYP2B6), 12) diclofenac 4?-hydroxylation (CYP2C9), 13) S-mephenytoin 4?-hydroxylation (CYP2C19), 14) desipramine 2-hydroxylation (CYP2D6), 15) chlorzoxazone 6-hydroxylation (CYP2E1), 16) and testosterone 6b-hydroxylation (CYP3A4) 17) were used for assessing the respective CYP-catalytic probe activities. Metabolites of the above in vitro probe substrates were determined using the respective HPLC assay methods, as reported elsewhere. 10, 12, 13, [18] [19] [20] Inhibition study: Ketoconazole and TAO were used as CYP3A4 selective inhibitors. 21) Ketoconazole (1 mM) was coincubated with CAM under the incubation conditions described above. TAO (1 mM) was preincubated with microsomes and the NADPH generating system for 15 min, before addition of CAM to initiate the reaction. The eŠects of inhibitors on the rates of Ndemethylation and 14-(R )-hydroxylation or metabolic clearance of CAM using pooled human liver microsomes were compared with the control values and expressed as percentages of the respective control values.
Immunoinhibition study: The antibody used in this study was a polyclonal antibody raised in rabbits against rat CYP3A1. This antibody cross-reacts with human CYP3A4 W 5 and inhibits approximately 95z of the testosterone 6b-hydroxylation catalyzed by the rat and human CYP3A subfamily, but does not inhibit the activities of CYP1A2, CYP2A6, CYP2B6, CYP2C8 W 9, CYP2D6 and CYP2E1 (Amersham, Tokyo, Japan). The immunoinhibition studies were performed by preincubating pooled human liver microsomes (0.3 mg W mL) with various concentrations of anti-CYP3A4 W 5 antibodies or preimmune rabbit IgG (0-2.5 mg IgG W mg microsomal protein) in 0.1 mM potassium phosphate buŠer (pH 7.4) for 30 min on ice. CAM and other components of the incubation medium were added, and the rates of N-demethylation and 14-(R )-hydroxylation or metabolic clearance of CAM were assessed as described above.
Determination of Km and Vmax for the metabolism of CAM: Kinetic parameters for the N-demethylation and 14-(R )-hydroxylation were obtained by incubating The intrinsic clearance (CL int ) of CAM was estimated form the volume of medium and the half-life of substrate disappearance as described in the text. CAM (5¿100 mM) with human liver microsomes (H161) or recombinant CYP3A4 under linear conditions with respect to protein concentration and time of incubation. Since the formation of both metabolites followed simple Michaelis-Menten kinetic behavior, Km and V max values were estimated by graphical analysis of Eadie-Hofstee plots.
Data analysis: Correlation coe‹cients (r) were determined by the least-squares linear regression analysis. The mean kinetic values were compared by Student's t-test for unpaired data (SAS system for Windows, Ver.6.10). P values º0.05 were considered statistically signiˆcant.
Results
The formation rates of metabolites and intrinsic clearance of CAM: CLint for the disappearance of CAM (1 mM) and the rates of N-demethylation and 14-(R )-hydroxylation of CAM (100 mM) are given in Table 1 . The mean (±SD) value of CLint was 43.6±23.0 mL W min W mg, while those for N-demethylation and 14-(R )-hydroxylation were 0.344±0.173 and 0.251± 0.136 nmol W min W mg, respectively.
Correlation study: The results of correlation between the CLint of CAM and marker enzyme activities and between the formation rates of metabolites and marker enzymes are summarized in Table 2 . There was an excellent correlation (r＝0.957, pº0.001) between the CLint values of CAM and testosterone 6b-hydroxylation activity (Fig. 1a) . CLint values of CAM were also signiˆcantly correlated with coumarin 7-hydroxylation activity (r＝0.685, pº0.05) and S-mephobarbital Ndemethylation activity (r＝0.752, pº0.05), although there were no signiˆcant correlations between the CLint of CAM and other metabolic activities of probe substrates used in the present study.
The formation rates of both N-demethyl-CAM and 14-(R )-hydroxyl-CAM signiˆcantly correlated with the testosterone 6b-hydroxylation activity as shown in Fig. 1b (r＝0.947-0 .954, pº0.001), and with S- Fig. 1 . Relationships between the intrinsic clearances of CAM and testosterone 6b-hydroxylation activities (a) and between formation rates of major metabolites of CAM and testosterone 6b-hydroxylation activities (b) in microsomes from nine diŠerent human livers. mephenytoin 4?-hydroxylation activity (r＝0.825, pº0.01; 0.791, pº0.05). No statistically signiˆcant relationships were observed between N-demethylation or 14-(R )-hydroxylation of CAM and the other speciˆc CYP enzyme activities investigated. However, the rates of N-demethylation and 14-(R )-hydroxylation of CAM were highly correlated with each other (r＝0.993, pº0.001) in nine diŠerent human liver microsomes (Fig. 2) , suggesting that the same CYP isoform(s) is involved in the both metabolic pathways.
Metabolism by recombinant CYP isoform: Among the recombinant CYP isoforms expressed in lymphoblastoid cell lines, only CYP3A4 revealed the signiˆcant metabolic clearance for CAM (Fig. 3) . Similarly, with respect to the formation rates of N-demethyl-CAM and 14-(R )-hydroxyl-CAM, CYP3A4 revealed the highest catalytic activity, while CYP2D6 only showed slight activity for N-demethylation.
Although the microsomes of baculovirus-infected insect cells that contained about 10-times greater amounts of CYP2C19 than those in microsomes of lymphoblastoid cells were examined separately, they did not exhibit any appreciable activity for the N-demethylation, 14-(R )-hydroxylation or disappearance of CAM (data not shown).
Chemical inhibition study: The eŠects of ketoconazole (1 mM) and TAO (1 mM) on the metabolism of CAM in pooled human liver microsomes are shown in Fig. 4 . These two widely used selective inhibitors of CYP3A4 potentially reduced the CLint of CAM and strongly inhibited the formation of N-demethyl-CAM and 14-(R )-hydroxyl-CAM. The reductions of CLint by ketoconazole and TAO were 96z and 92z, respectively. The inhibitions by ketoconazole and TAO of Ndemethylation and 14-(R )-hydroxylation were À84z and À80z, respectively.
Immunoinhibition study: The suppression of the metabolic clearance of CAM and the inhibition of metabolite formation by the addition of anti-CYP3A4 W 5 polyclonal antibody are shown in Fig. 5 . The addition of antibody to the incubation medium reduced the CLint of CAM by 89z at a concentration of 2.5 mg IgG W mg microsomal protein. Similarly, the rates of N-demethylation and 14-(R )-hydroxylation of CAM (10 mM) were reduced markedly by the addition of antibody in a concentration-dependent manner and those activities were almost completely abolished by 1.25 and 2.5 mg IgG W mg microsomal protein, respectively. Kinetic parameters: The kinetic parameters for Ndemethylation and 14-(R )-hydroxylation of CAM in human liver microsomes and in microsomes of recombinant human CYP3A4 are listed in Table 3 . The apparent Km value of 14-(R )-hydroxylation in recombinant human CYP3A4 (18.6±10.6 mM) was comparable with that obtained with human liver microsomes (25.2± 1.0mM). However, the apparent Km value of N-demethylation in microsomes of recombinant human CYP3A4 (14.4±2.6 mM) was lower than that in the human liver microsomes (52.5±16.6 mM). The sums of V max W K m values for N-demethylation and 14-(R )-hydroxylation were 65z of the CLint of CAM in human liver microsomes (62.9 mL W min W mg protein) and 83z in recombinant human CYP3A4 (19.7 mL W min W mg protein).
Discussion
The major human CYP isoform(s) involved in the in vitro metabolism of CAM was identiˆed by measuring the disappearance rate of parent compound and com- pared with those by measuring the formation rate of metabolites. The results with respect to the disappearance of CAM indicate that CYP3A4 is a principal isoform responsible for the overall metabolic clearance of CAM in human liver microsomes. This is supported by the following evidence: 1) disappearance rate of CAM was highly correlated with the testosterone 6b-hydroxylation activity, a marker for CYP3A4, in the same panel of microsomes as those used for the metabolites formation study (Fig. 2, Table 2 ); 2) CYP3A4 revealed the metabolic activity for the disappearance of CAM among the 11 isoforms of recombinant human CYP, while the other CYP isoforms exhibited no signiˆcant metabolic activity (Fig. 3); 3) ketoconazole and TAO, selective inhibitors of CYP3A4, reduced the CLint of CAM (Fig. 4) ; and 4) the CL int of CAM was almost completely suppressed by the addition of anti-CYP3A4 W 5 antibodies to the incubation mixture (Fig. 5) . Although our study revealed the signiˆcant correlations between the CLint of CAM and CYP2A6-selective coumarin 7-hydroxylation activity and CYP2B6-selective S-mephobarbital N-demethylation activity ( Table 2) , those isoforms do not appear to be involved in the clearance of CAM, since the correlation coe‹cient between the CAM clearance and activity of CYP2A6 or CYP2B6 was lower than that between the CAM clearance and CYP3A4 activity ( Table 2) . Furthermore, the correlation line between the CAM clearance and CYP3A4 activity appears to pass through the origin that has no intercept signiˆcantly larger than zero (data not shown). In addition, neither recombinant CYP2A6 nor CYP2B6 was capable of metabolizing CAM (Fig. 3) . Therefore, the observed correlation between the metabolic clearance of CAM and CYP2A6 or CYP2B6 activity may be derived from the fact that CYP3A4 activity signiˆcantly correlated with both CYP2A6 (r＝0.729, pº0.05) and CYP2B6 (r＝0.671, pº0.05) activities in the panel of liver microsomes used in the present study.
Regarding the possibility that CYP3A5 also catalyze the metabolism of CAM, Williams et al. 22) recently reported the capability of baculovirus-expressed CYP3A5 to metabolize CAM. Although CYP3A5 is generally a minor component of total CYP3A 23) and only expressed in 25z of individuals and the expression level is usually lower as compared to CYP3A4, 24) recent evidence indicates that CYP3A5 may represent more than 50z of the total CYP3A in some individuals possessing the CYP3A5*1 allele. 25) However, CYP3A5 appears to play a relatively minor role based on the reported low clearance values of CYP3A5 relative to that of CYP3A4 for the metabolism of CAM. 22) Therefore, CYP3A4 appears to be the predominant CYP isoform involved in the metabolic clearance of CAM in human liver microsomes.
The formation rates of metabolites conˆrmed the predominant role of CYP3A4 in two major metabolic pathways, N-demethylation and 14-(R )-hydroxylation, of CAM in human liver microsomes. In the correlation study, formation rates of both metabolites signiˆcantly correlated with the CYP3A4-selective testosterone 6b-hydroxylation activity (r＝0.947-0.954, pº0.001) in nine diŠerent human liver microsomes ( Table 2) . Although a signiˆcant correlation with CYP2C19-selective S-mephenytoin 4?-hydroxylation activity (r＝ 0.791-0.825, pº0.05) was also observed ( Table 2) , this isoform does not appear to be involved in the both metabolic pathways of CAM. This is because, no metabolic activity of CAM was observed with recombinant CYP2C19 from human B lymphoblastoid cells (Fig. 3) or even with overexpressed CYP2C19 from baculovirusinfected insect cells. Therefore, this correlation appears to be derived from the signiˆcant correlation between CYP2C19 and CYP3A4 activities in the panel of liver microsomes used in the present study (r＝0.732, pº0.05).
Although recombinant CYP2D6 was capable of catalyzing N-demethylation (Fig. 3) , it does not appear to play a signiˆcant role in the metabolism of CAM. This is because, there was no signiˆcant correlation between N-demethylation of CAM and CYP2D6-selective desipramine 2-hydroxylation activity ( Table 2) , and quinidine (5 mM), a selective inhibitor of CYP2D6, did not inhibit N-demethylation of CAM (unpublished observation). Moreover, CYP2D6 in the recombinant system used in the present study is overexpressed and its content is more than 10-fold greater than that present in usual human liver microsomal preparations (data provided by Gentest). In addition, the predominant role of CYP3A4 in N-demethylation and 14-(R )-hydroxylation of CAM was further conˆrmed by theˆndings that those activities were strongly (À80z) inhibited by the CYP3A4 selective inhibitors, ketoconazole (1 mM) and TAO (1 mM), and almost completely abolished by anti-CYP3A4 W 5 antibody (Figs. 4 and 5) .
In the present study, we found that the sum of Vmax W Km values for N-demethylation and 14-(R )-hydroxylation is 65z of CLint derived from the disappearance of CAM in human liver microsomes. Theˆnding suggests that N-demethylation and 14-(R )-hydroxylation are the major metabolic pathways of CAM in human liver microsomes, and also suggests that there may be other metabolic pathways in the overall metabolism of CAM. However, the results of the present study indicate that CYP3A4 plays a predominant role in the overall metabolism of CAM as well as the N-demethylation and 14-(R )-hydroxylation of CAM. Therefore, CYP2C19 does not appear to be mainly involved, even if any, in the overall metabolism of CAM in human liver microsomes.
Based on the present results, the gene-dose eŠect of the defective alleles of CYP2C19 on the mean AUC of CAM reported previously 7) could not be explained by the contribution of CYP2C19 to the metabolism of CAM. One of the possibilities to explain the gene-dose eŠect is the more pronounced interference with the CYP3A4 mediated CAM metabolism by high concentration of omeprazole in the CYP2C19 poor metabolizer group. Omeprazole has been found to be a weak inhibitor of CYP3A4 in vitro 26) and does not inhibit CYP3A4 activity in vivo. 27, 28) The typical K i values of omeprazole are 84.4 mM 29) for CYP3A-mediated dextromethorphan N-demethylation 30) and 367.5 mM 31) for oxidation of nifedipine, 32) though a recent report has shown relatively low Ki values of 0.4 mM and 45.6 mM 31) for the metabolism of CYP3A substrates cisapride 33) and simvastatin, 34) respectively. Although the Ki value of omeprazole for the CYP3A4 mediated CAM metabolism is not known, considering the high plasma concentration of omeprazole (¿5.5 mM) in the CYP2C19 poor metabolizer group, 7) the possibility that metabolism of CAM was inhibited by omeprazole can not be ruled out.
Another possibility is the eŠect of omeprazole on the stability of CAM. Gustavson et al. 35) has reported that administration of CAM with omeprazole produces higher plasma concentration of CAM with higher mean gastric pH (5.7 vs 3.1) than does the administration of CAM with placebo. CAM is more acid stable than erythromycin, however, some degradation of CAM is likely to occur in the stomach at typical gastric pH. They speculated that the increase in the plasma concentration of CAM might be due to the elevated absorption of more intact CAM by the eŠect of omeprazole on gastric pH. Therefore, the gene-dose eŠect of the defective alleles of CYP2C19 on the mean AUC of CAM reported previously 7) might be derived from the eŠect of omeprazole on gastric pH which is dependent on CYP2C19 genotype status. 35) In conclusion, the present study using human liver microsomes and recombinant human CYP isoforms indicates that CYP3A4 is the major isoform involved in the overall metabolic clearance of CAM as well as in the formation of 14-(R )-hydroxy-CAM and N-demethyl-CAM. CYP2C19 does not appear to be involved in the overall metabolism of CAM at least in human liver microsomes. The results also showed that the sum of Vmax W Km values for N-demethylation and 14-(R )-hydroxylation is 65z of CLint derived from the disappearance of CAM in human liver microsomes. A combination of the determination of disappearance rate of a parent compound and the formation rate of metabolites may be a useful approach for estimating the percentage contribution of the formation of metabolites to the overall metabolic clearance of a parent compound in vitro.
